BOSTON SCIENTIFIC, GUIDANT AWAIT APPROVAL

If it hopes to stay on track with its acquisition timetable, Boston Scientific Corp. has about six weeks to complete its $27.2 billion deal to buy medical device maker Guidant Corp. But so far, the companies are still awaiting regulatory approval in the U.S. and Europe as well as the endorsement of shareholders. Boston Scientific spokesman Paul Donovan said Tuesday both companies plan to have shareholder votes on the cash-and-stock deal by the end of next month.
Casper Star Tribune